Drug Name: Rolvedon
Active Ingredient: eflapegrastim
Indications: To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia
Approval Date: 9/9/2022
Company: Spectrum Pharmaceuticals, Inc
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761148Orig1s000Corrected_lbl.pdf